Top headlines: Rupee at 5-week high; Infosys says no to moonlighting

As many as 34 new drugs were added and 26 dropped from an updated list of essential medicines that will lead to prices being fixed, said the government on Tuesday.

rupee
Photo: Bloomberg
BS Web Team New Delhi
2 min read Last Updated : Sep 13 2022 | 5:21 PM IST
Rupee climbs to 5-week high on dollar inflows, breaches key level

The Indian rupee rose to an over one-month high against the U.S. currency on Tuesday, spurred by foreign inflows into local debt and equity markets.

The rupee closed at 79.1475 per U.S. dollar, compared with the previous close of 79.5225, notching up its best session this month. Read more

FM Sitharaman asks India Inc why it is hesitant to invest in manufacturing

Finance Minister Nirmala Sitharaman on Tuesday sought to know from industry what is holding it back from investing in manufacturing, even though foreign investors show confidence in India.

Drawing parallel between India Inc and mythological character 'Hanuman', Sitharaman said the government is willing to engage with the industry and take policy action. Read more

Essential medicines list updated, adds 34 new drugs and drops 26

As many as 34 new drugs were added and 26 dropped from an updated list of essential medicines that will lead to prices being fixed, said the government on Tuesday.

The National List of Essential Medicines (NLEM 2022) has 384 drugs, up from 376 covered in 2015. Read more

'No Double Lives': Infosys email warns employees against moonlighting

IT services firm Infosys has warned employees it will not allow moonlighting and violations may lead to termination, mailing them about rules days after Wipro chairman Rishad Premji called the trend "cheating--plain and simple".

Bengaluru-based Infosys sent an email to employees titled "No Double Lives" and said: “…dual employment is not permitted as per the Employee Handbook and the Code of Conduct.” Read more

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Nirmala SitharamanIndian rupeeUS DollarInfosys MoonlightAnti cancer drugsMedicinesIndia Inc

Next Story